The achievements of the United States life sciences industry over the past two years have been nothing short of astounding. In a previously unimaginable time frame, the sector developed and produced multiple Covid-19 vaccines that were effectively distributed to hundreds of millions of people across the globe, and it was truly a willingness to collaborate within and across sectors that carried the day. Pharmaceutical and biopharmaceutical companies worked tirelessly to develop and manufacture vaccines and therapeutics, governments invested billions of dollars in the name of public health, and regulatory agencies like the FDA were able to accelerate their review processes to keep up with fast timelines. Meanwhile, advancements across therapeutic areas from cell and gene therapy to work on neurodegenerative diseases continued at a breakneck pace.
With a finish line to the Covid marathon hopefully in sight, Global Business Reports presents a timely review and analysis of the current state of the industry. Insights from the report are supported by conversations with leaders within top pharma companies like Janssen Pharmaceuticals and Pfizer; contract service providers including Cambrex, Syngene International, CordenPharma, and Quotient Sciences; chemicals producers and distributors such as Brenntag and BASF Pharma Solutions; key associations including PhRMA, PBOA, BioNJ, Biocom California, MassBio, and the Pennsylvania Biotechnology Center; and a host of leading voices across the financial, research, and technology services sectors.
Drawing from interviews conducted with over 80 industry leaders, the United States Life Sciences 2022 report brings readers up to speed on the current investment and regulatory climate as well as the overall health of the life sciences ecosystem. Importantly, it also features GBR’s assessment of certain emerging trends that may shape the landscape of a post-pandemic world.